Bio-Rad Laboratories, Inc.'s New SsoAdvanced™ Universal Supermixes Offer Superior Performance on Any Real-Time PCR Instrument

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Hercules, CA — May 29, 2013 — Bio-Rad Laboratories, Inc. today announced the launch of its SsoAdvanced universal supermixes

The new SsoAdvanced universal supermixes include the SsoAdvanced™ universal SYBR® Green supermix and the SsoAdvanced universal probes supermix.

Both supermixes include Bio-Rad’s patented Sso7d fusion enzyme, which provides the highest-quality data from the most challenging sample types. The enzyme’s performance is aided by an advanced formulation of surfactants, detergents, stabilizers, and other proprietary components, allowing the supermixes to be used across a wide range of cycling conditions, primer concentrations, and temperatures.

The meaning of the term “universal” is twofold:

· These supermixes are compatible with all qPCR platforms. Multiple passive reference dyes blended in Bio-Rad’s supermixes are particularly useful for researchers using qPCR instruments that require ROX fluorescent dyes. The supermixes eliminate the need to change reagents between experiments and instruments.

· These supermixes yield optimal performance across a broad range of challenging sample types and difficult target sequences, so they can be used with wide variety of qPCR applications, including gene expression studies, ChIP analyses, genotyping, and more.

The SYBR® Green supermix is optimized for dye-based qPCR and contains SYBR® Green I, whereas the probes supermix is formulated for probe-based qPCR (simplex or duplex). The SsoAdvanced universal supermixes complement Bio-Rad’s iTaq™ universal supermixes, which are suitable for most samples and targets.

For more information on Bio-Rad’s supermixes, please visit www.bio-rad.com/supermixes.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,300 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Richard Kurtz

Bio-Rad

510-741-5638

Richard_Kurtz@bio-rad.com

Ken Li

Chempetitive Group

312-997-2436 x 112

kli@chempetitive.com



Help employers find you! Check out all the jobs and post your resume

Back to news